Rajeev M. Shah is Director & 10% Owner at Vor Biopharma Inc. (VOR). They have made 38 open-market trades across 23 companies since 2016, most recently 2026-03-30.
CIK 0001619841
32 open-market purchases totalling $762.8M since 2016, against 6 sales. Across 32 scored buys the stock is up 3.1% at ninety days, and 1.4 points ahead of the S&P over the same stretch.
32 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 44% | 34% | 41% |
| Avg Move | +4.6% | -2.1% | +3.1% |
| Alpha | +4.6% | -4.1% | +1.4% |
| Scored | 32 | 32 | 32 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 83% | 83% |
| Avg Move | -2.8% | -19.9% | -28.9% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MLYS | BUY | 2026-03-27 | 2026-03-31 | $23.75 | $8.8M | -3.0% | -4.7% | -4.0% |
| VOR | SELL | 2025-10-15 | 2025-10-17 | $29.52 | $26.9M | -14.9% | -66.5% | -53.1% |
| SEPN | BUY | 2024-10-28 | 2024-10-30 | $18.00 | $75.1M | +17.4% | +16.7% | -26.2% |
| AVTE | BUY | 2024-06-17 | 2024-06-20 | $1.67 | $3.1M | +1.3% | +15.0% | +19.4% |
| HOWL | BUY | 2023-01-06 | 2023-01-10 | $2.21 | $4.1M | +40.4% | +24.9% | -8.3% |
| IMRA | BUY | 2022-12-08 | 2022-12-12 | $3.89 | $191K | -4.7% | +6.8% | +165.3% |
| IMRA | BUY | 2022-10-20 | 2022-10-24 | $3.92 | $440K | -7.3% | -2.0% | -6.6% |
| ANTX | BUY | 2022-08-03 | 2022-08-05 | $7.51 | $14K | +92.0% | -21.9% | +45.2% |
| ANTX | BUY | 2022-06-21 | 2022-06-23 | $7.99 | $2K | +1.7% | -10.8% | +9.9% |
| KALA | SELL | 2022-05-23 | 2022-05-25 | $0.49 | $2.2M | +0.2% | -7.7% | -22.2% |
| NKTX | BUY | 2022-04-26 | 2022-04-28 | $15.00 | $33.0M | -26.9% | -20.1% | -28.9% |
| CTKB | BUY | 2022-03-09 | 2022-03-11 | $12.86 | $16.3M | -14.4% | -17.6% | -16.3% |
| CTKB | BUY | 2022-03-04 | 2022-03-08 | $12.74 | $16.5M | -7.9% | -19.5% | -18.9% |
| CTKB | BUY | 2022-02-28 | 2022-03-02 | $12.95 | $11.4M | -8.0% | -17.8% | -26.6% |
| CTKB | BUY | 2022-02-17 | 2022-02-22 | $14.06 | $15.4M | -2.2% | -24.3% | -26.9% |
| ICVX | BUY | 2021-08-02 | 2021-08-04 | $15.00 | $40.0M | -1.8% | +21.2% | +6.7% |
| ABOS | BUY | 2021-07-06 | 2021-07-08 | $16.00 | $30.0M | +4.1% | -15.4% | -16.5% |
| AVTE | BUY | 2021-07-02 | 2021-07-06 | $14.00 | $39.0M | -22.0% | -31.0% | -1.8% |
| HOWL | BUY | 2021-05-04 | 2021-05-06 | $16.00 | $27.4M | -13.9% | -13.3% | +15.6% |
| STSA | BUY | 2021-02-26 | 2021-03-02 | $5.68 | $14.0M | -1.4% | -11.5% | -20.7% |
| PCVX | SELL | 2020-10-07 | 2020-10-09 | $50.79 | $27.0M | -13.4% | -24.7% | -43.2% |
| PCVX | SELL | 2020-09-29 | 2020-10-01 | $50.81 | $22.5M | +6.7% | -20.7% | -38.1% |
| ITOS | BUY | 2020-07-28 | 2020-07-29 | $19.00 | $27.1M | +52.1% | +55.9% | +29.0% |
| NKTX | BUY | 2020-07-14 | 2020-07-16 | $18.00 | $60.0M | -26.1% | -27.1% | -19.2% |
| RYTM | SELL | 2020-06-25 | 2020-06-29 | $23.06 | $6.9M | -3.0% | -4.7% | +3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| MLYS | 5,825,521 | $118.2M |
| ETNB | 4,331,081 | $64.3M |
| CTKB | 12,202,700 | $64.2M |
| SEPN | 1,695,515 | $61.6M |
| SLDB | 8,709,882 | $48.3M |
| IMRA | 3,250,724 | $47.4M |
| KALV | 1,441,070 | $38.9M |
| VOR | 1,848,102 | $33.3M |
| ABOS | 19,103,785 | $32.3M |
| ITOS | 2,992,259 | $30.4M |
| AVTE | 7,893,678 | $21.2M |
| NKTX | 7,805,129 | $14.1M |
| ANTX | 3,773,417 | $12.8M |
| FULC | 3,109,704 | $11.4M |
| SPRY | 2,106,774 | $8.4M |
| ICVX | 466,902 | $7.1M |
| STSA | 5,155,854 | $5.7M |
| HOWL | 5,701,056 | $5.6M |
| BDTX | 2,277,978 | $3.9M |
| KALA | 9,479,808 | $1.8M |
| ITRM | 11,651,597 | $367K |
| Total | $2.2B |
Shares reported on the most recent Form 4, priced at the 2026-03-31 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Scored | 6 | 6 | 6 |